Natdac combines agents that are individually approved for HIV (tenofovir) and hepatitis C (daclatasvir, sofosbuvir). While the pharmacologic rationale supports activity against both viruses, the fixed-dose combination has not been specifically approved for simultaneous treatment; clinicians must evaluate the individual components within approved regimens.
Mild gastrointestinal upset is a common side effect. Taking the tablet with food or a small snack may reduce nausea. If symptoms persist for more than a few days, contact your healthcare provider for further assessment.
St. John’s wort, a strong CYP3A4 inducer, can lower daclatasvir levels, potentially reducing antiviral efficacy. Patients should disclose all herbal and over-the-counter products to their prescriber before initiating therapy.
Natdac tablets are classified as prescription medicines. Carry the original pharmacy label, a copy of the prescription, and declare the medication at customs if required by the destination country’s regulations.
Natdac tablets are round, white, and marked with the imprint “ND60”. This imprint assists pharmacists and patients in confirming the correct medication during dispensing and self-administration.
All three active ingredients have good oral absorption regardless of food intake. However, taking the tablet with water and, if desired, a light meal can improve tolerability, especially for patients prone to stomach upset.
Baseline assessments should include renal function (eGFR), hepatic enzymes (ALT/AST), hepatitis C viral load, and HIV-RNA level if applicable. Additional tests may be ordered based on patient history.
None of the components are commonly screened for in workplace drug-testing panels. However, tenofovir and its metabolites may be detectable in specialized toxicology assays.
Fixed-dose combinations can improve adherence by reducing pill burden, but comparative efficacy data for this specific trio are not available. Clinicians should consider individual patient factors when selecting a regimen.
Do not discard tablets in household waste. Return unused medication to a local pharmacy or use the NHS “medicines disposal” service to ensure safe and environmentally responsible disposal.
Natdac is a fixed-dose antiviral pill that contains three active ingredients: Daclatasvir, Sofosbuvir, and Tenofovir Disoproxil. The tablet is manufactured as a 60 mg oral formulation. These agents belong to the broader class of antiviral medicines used to treat chronic viral infections such as hepatitis C and human immunodeficiency virus (HIV).
Natdac’s regulatory status in the United Kingdom has not been publicly disclosed by the Medicines and Healthcare products Regulatory Agency (MHRA). Consequently, the information below is based on the known pharmacology and clinical experience of the individual components rather than on a specific product approval.
Daclatasvir is an NS5A inhibitor. It binds to the non-structural protein 5A of hepatitis C virus (HCV), disrupting the formation of the viral replication complex and halting viral RNA synthesis.
Sofosbuvir is a nucleotide analogue NS5B polymerase inhibitor. After intracellular activation, it mimics the natural building block of viral RNA, leading to premature chain termination during HCV replication.
Tenofovir Disoproxil is a prodrug of tenofovir, a reverse-transcriptase inhibitor. It is phosphorylated inside cells to the active diphosphate form, which competes with natural nucleotides and terminates DNA synthesis by HIV-1 reverse transcriptase and hepatitis B virus polymerase.
Together, the three agents target distinct steps in viral replication pathways, offering a broad antiviral spectrum that includes both RNA (HCV) and retroviral (HIV) mechanisms.
| Ingredient | Primary approved indication (UK) | Typical patient population | ||-|-| | Daclatasvir | Chronic hepatitis C (genotype 1-4) | Adults with compensated liver disease | | Sofosbuvir | Chronic hepatitis C (all genotypes) | Adults and adolescents ≥12 years with adequate renal function | | Tenofovir Disoproxil | HIV-1 infection (as part of combination therapy) and chronic hepatitis B | Adults and children ≥2 years for HIV; adults for hepatitis B |
Natdac combines these agents in a single tablet; however, no specific combination approval has been identified. Healthcare providers may consider the individual indications of each component when evaluating therapeutic options.
These reactions are usually transient and resolve without medical intervention. If symptoms persist or worsen, the prescriber should be consulted.
Because Natdac contains three agents, the potential for pharmacokinetic interactions is higher than with single-component therapy. A comprehensive medication review is essential before starting treatment.
Because the fixed-dose combination is not a standard therapy, dosing may be individualized based on the patient’s viral profile, renal function, and co-medications.
Regular follow-up appointments allow timely identification of adverse effects and therapeutic adjustments.
This article provides educational information about Natdac and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
